The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis

Am J Kidney Dis. 2016 Oct;68(4):554-563. doi: 10.1053/j.ajkd.2016.03.418. Epub 2016 Apr 30.

Abstract

Background: Left ventricular mass (LVM) is a widely used surrogate end point in randomized trials involving people with chronic kidney disease (CKD) because treatment-induced LVM reductions are assumed to lower cardiovascular risk. The aim of this study was to assess the validity of LVM as a surrogate end point for all-cause and cardiovascular mortality in CKD.

Study design: Systematic review and meta-analysis.

Setting & population: Participants with any stages of CKD.

Selection criteria for studies: Randomized controlled trials with 3 or more months' follow-up that reported LVM data.

Intervention: Any pharmacologic or nonpharmacologic intervention.

Outcomes: The surrogate outcome of interest was LVM change from baseline to last measurement, and clinical outcomes of interest were all-cause and cardiovascular mortality. Standardized mean differences (SMDs) of LVM change and relative risk for mortality were estimated using pairwise random-effects meta-analysis. Correlations between surrogate and clinical outcomes were summarized across all interventions combined using bivariate random-effects Bayesian models, and 95% credible intervals were computed.

Results: 73 trials (6,732 participants) covering 25 intervention classes were included in the meta-analysis. Overall, risk of bias was uncertain or high. Only 3 interventions reduced LVM: erythropoiesis-stimulating agents (9 trials; SMD, -0.13; 95% CI, -0.23 to -0.03), renin-angiotensin-aldosterone system inhibitors (13 trials; SMD, -0.28; 95% CI, -0.45 to -0.12), and isosorbide mononitrate (2 trials; SMD, -0.43; 95% CI, -0.72 to -0.14). All interventions had uncertain effects on all-cause and cardiovascular mortality. There were weak and imprecise associations between the effects of interventions on LVM change and all-cause (32 trials; 5,044 participants; correlation coefficient, 0.28; 95% credible interval, -0.13 to 0.59) and cardiovascular mortality (13 trials; 2,327 participants; correlation coefficient, 0.30; 95% credible interval, -0.54 to 0.76).

Limitations: Limited long-term data, suboptimal quality of included studies.

Conclusions: There was no clear and consistent association between intervention-induced LVM change and mortality. Evidence for LVM as a valid surrogate end point in CKD is currently lacking.

Keywords: LVM regression; Left ventricular mass (LVM); cardioprotection; cardiovascular mortality; chronic kidney disease (CKD); erythropoiesis-stimulating agent (ESA); left ventricular hypertrophy; meta-analysis; nitrate; renin-angiotensin-aldosterone system (RAAS) inhibitor; surrogate endpoint; surrogate outcome.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Biomarkers
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / mortality*
  • Cardiovascular Diseases / pathology
  • Cause of Death
  • Heart Ventricles / pathology*
  • Humans
  • Organ Size
  • Randomized Controlled Trials as Topic
  • Renal Insufficiency, Chronic / complications*
  • Renal Insufficiency, Chronic / mortality*
  • Reproducibility of Results

Substances

  • Biomarkers